Abrdn Healthcare Investors
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel R. Omstead
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Federal Street Philadelphia PA United States of America 02110
- IPO Date
- Apr 23, 1987
- CIK
- 0000805267
- Website
- teklacap.com
- Similar Companies
- Business
- Abrdn Healthcare Investors is a closed-ended equity mutual fund primarily engaged in investing in public equity markets globally, focusing on the healthcare sector. The fund principally targets growth stocks of small-cap companies operating in biotechnology, medical devices, pharmaceuticals, diagnostics, managed healthcare, healthcare information technology, and healthcare services. It employs fundamental analysis to select companies based on market position, experienced management, technological expertise, and capital generation or acquisition capabilities. The fund benchmarks its performance against the Nasdaq Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Founded in 1986 and domiciled in the United States, Abrdn Healthcare Investors is managed by Abrdn Inc. The fund's main products and services consist of investment in a diversified portfolio of healthcare-related securities including biotechnology, pharmaceuticals, medical equipment, and healthcare technology companies. Its investment strategy emphasizes above-average long-term growth in revenues and earnings from businesses within the healthcare industry across global markets. Recent major changes include a 25% increase in its managed distribution policy rate from 8% to 10% on a rolling average basis as of early 2024, reflecting confidence in the sector's prospects. The fund also renewed its share repurchase program allowing open-market purchases of up to 12% of outstanding common shares through mid-2024 to enhance shareholder value and reduce the discount to net asset value. These developments align with the fund's strategic emphasis on sustainable cash distributions and capital appreciation amid a robust healthcare market environment. Abrdn Healthcare Investors continues to maintain strong financial positioning through these initiatives while leveraging its expertise in healthcare investments globally.
HQH: GLP-1 Market Growth Offers Upside But Portfolio Structure A Bit Inefficient
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
Variable Payouts, Permanent Income: Why I'm Buying These 11% Yields Today
I Demand Recurrent Income For My Retirement
Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
5 ‘Healthy' Dividends Paying Up To 14.1%
HQH: Strong Returns Fuel Higher Payout, But Valuation Not As Compelling (Downgrade)
abrdn Healthcare Investors (NYSE:HQH) Short Interest Up 361.3% in February
Be The General Contractor: Build Your Double-Digit-Yielding Portfolio
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
HQH: Sentiment And Fundamentals Disconnect Presents Opportunity
2 Picks To Turn Savings Into Retirement Paychecks: Yields +10%
Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
This Is How I Would Invest $100,000 In 2026
30%+ Total Returns In 2025: Embrace Our 3 High-Income Momentum Picks For 2026
4 Closed-End Fund Buys In The Month Of November 2025
The Flavor Of Resilience: Why Essential Sectors Still Deliver; Yields +11%
HQH: Seeing Strong Recent Returns While Attractively Discounted
ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS
HQH: Severely Underperforms Peers (Rating Downgrade)